1. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Issue 5 (May 2019) Authors: Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze... Journal: Lancet oncology Issue: Volume 20:Issue 5(2019) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Issue 7 (July 2019) Authors: Clark, Richard E; Polydoros, Fotios; Apperley, Jane F; Milojkovic, Dragana; Rothwell, Katherine; Pocock, Christopher; Byrne, Jennifer; de Lavallade, Hugues; Osborne, Wendy; Robinson, Lisa; O'Brien, Stephen G; Read, Lucy; Foroni, Letizia; Copland, Mhairi Journal: Lancet Issue: Volume 6:Issue 7(2019) Page Start: e375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Issue 5 (May 2019) Authors: Kizilors, Aytug; Crisà, Elena; Lea, Nicholas; Passera, Roberto; Mian, Syed; Anwar, Jamal; Best, Steve; Nicolini, Franck E; Ireland, Robin; Aldouri, Maadh; Pocock, Christopher; Corbett, Tim; Gale, Richard; Bart-Smith, Emily; Weston-Smith, Simon; Wykes, Clare; Kulasekararaj, Austin; Jackson, Sophie... Journal: Lancet Issue: Volume 6:Issue 5(2019) Page Start: e276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic. Issue 1 (19th November 2021) Authors: Avenoso, Daniele; Milojkovic, Dragana; Clark, James; Pocock, Christopher; Potter, Victoria; Yallop, Deborah; Hannah, Guy Journal: EJHaem Issue: Volume 3:Issue 1(2022) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial. (20th May 2020) Authors: Gleeson, Mary; Counsell, Nicholas; Cunningham, David; Lawrie, Anthony; Clifton‐Hadley, Laura; Hawkes, Eliza; McMillan, Andrew; Ardeshna, Kirit M.; Burton, Cathy; Chadwick, Nick; Gambell, Joanna; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Radford, John; Davies, John; Turner, Deborah; Kruger,... Journal: British journal of haematology Issue: Volume 192:Number 6(2021) Page Start: 1015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial. (1st August 2016) Authors: Gleeson, Mary; Hawkes, Eliza A.; Cunningham, David; Chadwick, Nick; Counsell, Nicholas; Lawrie, Anthony; Jack, Andrew; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Ardeshna, Kirit M.; Radford, John; McMillan, Andrew; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter W.M.; Gambell, ... Journal: British journal of haematology Issue: Volume 175:Number 4(2016) Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. (29th December 2016) Authors: Varghese, Abraham M.; Howard, Dena R.; Pocock, Christopher; Rawstron, Andy C.; Follows, George; McCarthy, Helen; Dearden, Claire; Fegan, Christopher; Milligan, Donald; Smith, Alexandra F.; Gregory, Walter; Hillmen, Peter Journal: British journal of haematology Issue: Volume 176:Number 4(2017) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A case of Stage IA classical Hodgkin lymphoma with FDG‐avid tonsils. (12th February 2016) Authors: Vatopoulou, Theodora; Lawson, Charles; Pocock, Christopher Journal: British journal of haematology Issue: Volume 173:Number 2(2016) Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Issue 7 (July 2017) Authors: Clark, Richard E; Polydoros, Fotios; Apperley, Jane F; Milojkovic, Dragana; Pocock, Christopher; Smith, Graeme; Byrne, Jenny L; de Lavallade, Hugues; O'Brien, Stephen G; Coffey, Tony; Foroni, Letizia; Copland, Mhairi Journal: Lancet Issue: Volume 4:Issue 7(2017) Page Start: e310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. (1st October 2013) Authors: Collins, Graham P.; Parker, Anne N.; Pocock, Christopher; Kayani, Irfan; Sureda, Anna; Illidge, Tim; Ardeshna, Kirit; Linch, David C.; Peggs, Karl S. Journal: British journal of haematology Issue: Volume 164:Number 1(2014:Jan.) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗